<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676529</url>
  </required_header>
  <id_info>
    <org_study_id>PXS5505-MF-101</org_study_id>
    <nct_id>NCT04676529</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis</brief_title>
  <official_title>A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of&#xD;
      PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential&#xD;
      thrombocythemia (ET) myelofibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two phases: a dose escalation phase and a cohort expansion phase. The&#xD;
      dose escalation phase will follow a 3+3 design with a starting dose of 100 mg twice daily,&#xD;
      and a treatment duration of 4 weeks. Patients will be able to participate in more than one&#xD;
      dose level.&#xD;
&#xD;
      During the cohort expansion phase, 24 patients will be treated at the dose determined&#xD;
      appropriate based on safety, pharmacokinetic and pharmacodynamic results from the dose&#xD;
      escalation phase, for a period of up to 6 months. Patients from the dose escalation phase&#xD;
      will be able to participate in the cohort expansion phase.&#xD;
&#xD;
      There will be no washout period between dose escalation and dose expansion cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with serious and non-serious adverse events</measure>
    <time_frame>Day 0 to follow-up visit (28 days ± 1 day post-Tx discontinuation [dose escalation phase]; Day 0 to 28 days ± 1 day post-Tx discontinuation [cohort expansion phase])</time_frame>
    <description>Safety and tolerability of PXS-5505 in patients with myelofibrosis will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (C1hr=Cmax)</measure>
    <time_frame>Day 0, week 1 and week 4 (dose escalation), and Day 0, week 4, 12 and 24 weeks (cohort expansion phase only)</time_frame>
    <description>Pharmacokinetic parameters of PXS-5505 in patients with myelofibrosis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration (Cmin)</measure>
    <time_frame>Day 0, week 1 and week 4 (dose escalation), and Day 0, week 4, 12 and 24 weeks (cohort expansion phase only)</time_frame>
    <description>Pharmacokinetic parameters of PXS-5505 in patients with myelofibrosis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lysyl oxidase and lysyl oxidase-like 2 inhibition in plasma</measure>
    <time_frame>Day 0, week 1 and week 4 dose escalation, and at weeks 0, 4, 12 and 24 weeks (cohort expansion phase only)</time_frame>
    <description>Pharmacodynamic parameters of PXS-5505 in patients with myelofibrosis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow (BM) fibrosis (cohort expansion phase)</measure>
    <time_frame>Day 0, Week 12 and Week 24</time_frame>
    <description>Change in bone marrow fibrosis will be assessed according to European Consensus on grading of bone marrow fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (cohort expansion phase)</measure>
    <time_frame>At Week 12 and Week 24</time_frame>
    <description>Response rates as defined by International Working Group (IWG)-Myeloproliferative Neoplasms Research and Treatment criteria in patients with myelofibrosis administered PXS-5505 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in spleen volume (cohort expansion phase)</measure>
    <time_frame>Day 0, Week 12, and Week 24</time_frame>
    <description>Changes in spleen volume, as measured by computed tomography (CT) or magnetic resonance imaging (MRI) scan, in patients with myelofibrosis administered PXS-5505 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in myelofibrosis related symptoms (cohort expansion phase)</measure>
    <time_frame>Day 0, Week 12, and Week 24</time_frame>
    <description>Changes in myelofibrosis related symptoms based on Myelofibrosis-Symptom Assessment Form (MFSAF) v4.0 scores, in patients with myelofibrosis administered PXS-5505 will be determined. A higher score indicates worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hematological changes</measure>
    <time_frame>Day 0, Week 12, and 24</time_frame>
    <description>Hematological changes will be determined</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>PXS-5505, Dose Level 1, Escalation Phase (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive PXS-5505 dose level 1, twice daily for a period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXS-5505, Dose Level 2, Escalation Phase (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive PXS-5505 dose level 2, twice daily for a period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXS-5505, Dose Level 3, Escalation Phase (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive PXS-5505 dose level 3, twice daily for a period of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXS-5505, Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive PXS-5505 at the selected twice daily dose for a period of 24 weeks, or until progressive disease, unacceptable toxicity, dose-limiting toxicity or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXS-5505</intervention_name>
    <description>PXS-5505 is a hard gelatin capsule (size 0) with the additional excipients mannitol and magnesium stearate.</description>
    <arm_group_label>PXS-5505, Dose Level 1, Escalation Phase (Cohort A)</arm_group_label>
    <arm_group_label>PXS-5505, Dose Level 2, Escalation Phase (Cohort B)</arm_group_label>
    <arm_group_label>PXS-5505, Dose Level 3, Escalation Phase (Cohort C)</arm_group_label>
    <arm_group_label>PXS-5505, Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a pathologically confirmed established diagnosis of primary myelofibrosis or&#xD;
             post-essential thrombocythemia/polycythemia vera myelofibrosis as per the World Health&#xD;
             Organization 2016 diagnostic criteria (must include at least Grade 2 marrow fibrosis)&#xD;
&#xD;
          -  Patients who are not eligible for stem cell transplantation&#xD;
&#xD;
          -  Patients not currently on ruxolitinib or fedratinib (where available) treatment due to&#xD;
             ineligibility, or previously treated patients who have been discontinued for at least&#xD;
             2 weeks prior to first dose of study drug due to any of the following criteria:&#xD;
&#xD;
               -  Ineligible: Platelets &lt;50 x 10^9/L&#xD;
&#xD;
               -  Intolerant: Development of red blood cell transfusion dependence of at least two&#xD;
                  units/month for 2 months OR ≥Grade 3 adverse events of thrombocytopenia, anemia,&#xD;
                  hematoma, and/or hemorrhage while on treatment with ruxolitinib or fedratinib for&#xD;
                  at least 28 days&#xD;
&#xD;
               -  Refractory: &lt; 10% spleen volume reduction by MRI or CT, or &lt; 30% decrease from&#xD;
                  baseline in spleen volume by palpation after at least 3 months treatment with&#xD;
                  ruxolitinib or fedratinib&#xD;
&#xD;
               -  Relapsed: Regrowth to &lt; 10% spleen volume reduction by MRI or CT, or &lt; 30%&#xD;
                  decrease from baseline in spleen volume by palpation, following an initial&#xD;
                  response to ruxolitinib or fedratinib and after at least 3 months treatment&#xD;
&#xD;
          -  Have intermediate -2, or high-risk disease according to the International Working&#xD;
             Group prognostic scoring system (DIPSS);&#xD;
&#xD;
          -  Have symptomatic disease according to the MFSAF v4.0;&#xD;
&#xD;
          -  Life expectancy of six months or greater;&#xD;
&#xD;
          -  Must have adequate organ function as demonstrated by the following (within last 2&#xD;
             weeks):&#xD;
&#xD;
               -  Alanine aminotransferase and/or aspartate aminotransferase ≤ 2.5x upper limit of&#xD;
                  normal (ULN), or ≤ 4 x ULN (if upon judgment of the treating physician, it is&#xD;
                  believed to be due to extramedullary hematopoiesis [EMH] related to MF);&#xD;
&#xD;
               -  Direct bilirubin ≤ 1.5 x ULN; or ≤ 2 x ULN (if upon judgment of the treating&#xD;
                  physician, it is believed to be due to EMH related to MF);&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &gt; 50 mL/min&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status ≤ 2;&#xD;
&#xD;
          -  Men must agree to using one medically approved contraceptive measure and have their&#xD;
             partners agree to an additional barrier method of contraception for the duration of&#xD;
             the study and for 90 days after the last administration of study drug; women of&#xD;
             childbearing potential must use effective contraception&#xD;
&#xD;
          -  Cohort Expansion Phase only: A bone marrow biopsy must have been performed within 3&#xD;
             months prior to Day 1 treatment to establish the baseline fibrosis score or within 5&#xD;
             months of the re-initiation of treatment with PXS-5505 if subject participated in dose&#xD;
             escalation phase of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Greater than (&gt;) 10% blasts in peripheral blood (determined within last two weeks);&#xD;
&#xD;
          -  Prior splenectomy, or planning to undergo splenectomy, or splenic irradiation within 3&#xD;
             months prior to the first dose of study treatment&#xD;
&#xD;
          -  Any serious medical condition or psychiatric illness that would prevent (as judged by&#xD;
             the treating physician) the subject from signing the informed consent form or any&#xD;
             condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
&#xD;
          -  Known history of human immunodeficiency virus, active hepatitis C, or active hepatitis&#xD;
             B&#xD;
&#xD;
          -  History or presence of any form of cancer within the three years prior to enrolment,&#xD;
             with the exception of excised basal cell or squamous cell carcinoma of the skin, or&#xD;
             cervical carcinoma in situ or breast carcinoma in situ that has been excised or&#xD;
             resected completely and is without evidence of local recurrence or metastasis&#xD;
&#xD;
          -  Participation in an investigational drug or device trial within two weeks prior to&#xD;
             study Day 1 or within five times the half-life of the investigational agent in the&#xD;
             other clinical study, if known&#xD;
&#xD;
          -  Use of any cytotoxic chemotherapeutic agents, including hydroxyurea, corticosteroids&#xD;
             (prednisone ≤ 10 mg/day or corticosteroid equivalent is allowed), or immune modulators&#xD;
             (e.g., thalidomide) within two weeks and interferon use within four weeks prior to&#xD;
             study Day 1&#xD;
&#xD;
          -  Symptomatic congestive heart failure (New York Heart Association Classification Class&#xD;
             II), unstable angina, or unstable cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of surgery within two weeks prior to enrolment or anticipated surgery during&#xD;
             the study period or two weeks post-study&#xD;
&#xD;
          -  History of aneurysm&#xD;
&#xD;
          -  Any other condition that might reduce the chance of obtaining data required by the&#xD;
             protocol or that might compromise the ability to give truly informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>135 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett Charlton, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Pharmaxis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brett Charlton, MBBS</last_name>
    <phone>+61 414 987 338</phone>
    <email>Brett.charlton@pharmaxis.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinky Patel</last_name>
      <phone>0474 279 274</phone>
      <email>pinky.patel@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanley Cheung</last_name>
      <phone>08 8292 2240</phone>
      <email>stanley.cheung@icon.team</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>One Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Tan</last_name>
      <phone>61 403 306 839</phone>
      <email>peter.tan@oneclinicalresearch.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Perth Blood Institute</name>
      <address>
        <city>West Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shona Garlick</last_name>
      <phone>61 8 9200 5300</phone>
      <email>shona@pbi.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital - Internal Medicine</name>
      <address>
        <city>Busan</city>
        <state>Busan Gwang'yeogsi [Pusan-Kwan</state>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Won Sik Lee</last_name>
      <phone>+82-51-890-6407</phone>
      <email>wonsik112@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Daegu Gwang'yeogsi [Taegu-Kwan</state>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young Rok Do</last_name>
      <phone>82-53-250-7114</phone>
      <email>dyr1160@dsmc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Incheon Gwang'yeogsi [Inch'n-K</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Hoon Lee</last_name>
      <phone>82-460-2186</phone>
      <email>jhlee@gilhospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youngil Koh</last_name>
      <phone>82 2 2072 5179</phone>
      <email>go01@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System- Haemat</name>
      <address>
        <city>Seoul</city>
        <zip>03711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June-Won Cheong</last_name>
      <phone>82 2 2228 1970</phone>
      <email>JWCHEONG70@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chul Won Jung</last_name>
      <phone>82 2 3410 3452</phone>
      <email>chulwon1.jung@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Eun Lee</last_name>
      <phone>82 2 2258 6058</phone>
      <email>lee86@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombocythemia myelofibrosis</keyword>
  <keyword>PXS-5505</keyword>
  <keyword>Post polycythemia vera myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

